Literature DB >> 17178967

Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.

Michael A Horberg1, Leo B Hurley, Daniel B Klein, Stephen E Follansbee, Charles Quesenberry, Jason A Flamm, Gary M Green, Tye Luu.   

Abstract

HYPOTHESIS: Matched patients who test positive or negative for human immunodeficiency virus (HIV) who are undergoing comparable operations have similar complication rates and outcomes.
DESIGN: A retrospective study of surgical outcomes in HIV-infected and matched HIV-noninfected patients. Baseline information including HIV-related laboratory results, complications, and mortality was collected from printed and electronic records through 12 postoperative months.
SETTING: Kaiser Permanente Medical Care Program-Northern California, an integrated health organization with more than 3 million members, including more than 5000 HIV-infected members. PATIENTS: From July 1,1997, through June 30, 2002, HIV-infected members undergoing surgical procedures were matched 1:1 with HIV-noninfected patients undergoing surgical procedures by type, location, and year of surgery as well as by sex and age. Surgical procedures studied included appendectomy, arthrotomy or arthroscopy, bowel resection, cholecystectomy, cardiothoracic procedures, hernia repair, hysterectomy, hip or knee replacement, laparoscopy or laparotomy, and mammoplasty. MAIN OUTCOME MEASURES: Complications and mortality through 12 postoperative months, comparisons between HIV-infected and HIV-noninfected patients using matched-pair analyses, and HIV-infected cohort data were analyzed using the Fisher exact test and logistic regression.
RESULTS: Of 332 HIV-infected-HIV-noninfected pairs (mean age, 46.7 years; male sex, 91%), more than 95.0% were followed up through 12 postoperative months or until their deaths. Pairs had similar comorbidities, length of hospital stay, and number of postoperative surgical visits (P>.05, all variables). Among HIV-infected patients, the median years with HIV infection was 8.4 years; median CD4 T-cell count was 379/microL; 61.5% of these patients had an HIV RNA level less than 500 copies per milliliter; and 68% were receiving highly active antiretroviral therapy. Various complications were no more frequent among HIV-infected than in HIV-noninfected patients (11.1% vs 10.2%; P = .79), except for pneumonia (P = .04). There were more deaths within the 12 postoperative months in HIV-infected patients (10/332 vs 2/332; P = .02); 2 patients died 30 days or less after being operated on. Among HIV-infected patients, viral load of 30 000 copies per milliliter or more was associated with increased complications (adjusted odds ratio, 2.95; P = .007), but a CD4 cell count less than 200/muL was not associated with poorer outcomes.
CONCLUSIONS: The HIV-infected patients had more incidences of postoperative pneumonia and higher 12-month mortality, although other operative outcomes were comparable for HIV-infected and HIV-noninfected patients. Viral suppression to fewer than 30 000 copies per milliliter reduced surgical complications.

Entities:  

Mesh:

Year:  2006        PMID: 17178967     DOI: 10.1001/archsurg.141.12.1238

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  38 in total

1.  CD4 Count is Still a Valid Indicator of Outcome in HIV-Infected Patients Undergoing Major Abdominal Surgery in the Era of Highly Active Antiretroviral Therapy.

Authors:  A Chichom-Mefire; M Azabji-Kenfack; J Atashili
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

2.  HIV testing and epidemiology in a hospital-based surgical cohort in Malawi.

Authors:  Bryce E Haac; Anthony G Charles; Mitch Matoga; Sylvia M LaCourse; Dominic Nonsa; Mina Hosseinipour
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

3.  Are HIV-infected men vulnerable to prostate cancer treatment disparities?

Authors:  Adam B Murphy; Ramona Bhatia; Iman K Martin; David A Klein; Courtney M P Hollowell; Yaw Nyame; Elodi Dielubanza; Chad Achenbach; Rick A Kittles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-25       Impact factor: 4.254

4.  Short-term outcomes for lung cancer resection surgery in HIV infection.

Authors:  Keith M Sigel; Kimberly Stone; Juan P Wisnivesky; Lesley S Park; Chung Yin Kong; Michael J Silverberg; Sheldon Brown; Matthew Goetz; Maria C Rodriguez-Barradas; Cynthia Gibert; Fatma Shebl; Roger Bedimo; Roxanne Wadia; Joseph King; Kristina Crothers
Journal:  AIDS       Date:  2019-07-01       Impact factor: 4.177

5.  HIV Infection Is Not a Contraindication to Laparoscopic Sleeve Gastrectomy for Morbid Obesity.

Authors:  Nancy Panko; Gerrit Dunford; Rami Lutfi
Journal:  Obes Surg       Date:  2018-02       Impact factor: 4.129

6.  Gastrectomy and chemotherapy with S-1 for gastric cancer in a patient with acquired immunodeficiency syndrome.

Authors:  Ryuji Suzuki; Shunichi Ariizumi; Tatsuo Araida; Kazuhiko Hayashi; Masakazu Yamamoto
Journal:  Int J Clin Oncol       Date:  2010-09-02       Impact factor: 3.402

7.  Effect of CD4+ T-lymphocyte count on hospital outcome of elective general thoracic surgery patients with human immunodeficiency virus.

Authors:  Satoshi Nagasaka; Hirohisa Yazaki; Hideyuki Ito; Shin-ichi Oka; Hiromi Kuwata; Ayako Seike; Shinsuke Kitazawa; Shoji Fukuda; Shigeru Hosaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-11-15

Review 8.  Gynecologic issues in the HIV-infected woman.

Authors:  Helen E Cejtin
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

Review 9.  Human immunodeficiency disease: how should it affect surgical decision making?

Authors:  T E Madiba; D J J Muckart; S R Thomson
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

10.  Comparison of in-hospital morbidity and mortality in HIV-infected and uninfected children after surgery.

Authors:  Jonathan S Karpelowsky; Alastair J W Millar; Nelleke van der Graaf; Guido van Bogerijen; Heather J Zar
Journal:  Pediatr Surg Int       Date:  2012-08-26       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.